DEF 14A: Inogen's 2024 Proxy Statement: Stockholder Meeting to Address Director Elections, Auditor Ratification, Executive Pay, and Equity Incentive Plan

Inogen's upcoming Annual Meeting of Stockholders on June 5, 2024, will address key proposals including the election of directors, ratification of the independent auditor, executive compensation, and approval of an amended equity incentive plan.

Summary

• Inogen, Inc. will hold its Annual Meeting of Stockholders virtually on June 5, 2024, at 10:00 a.m. Pacific Time.
• Stockholders will vote on the election of two Class I directors, ratification of Deloitte & Touche LLP as the independent auditor, an advisory vote on executive compensation, and approval of the Amended and Restated 2023 Equity Incentive Plan.
• The Board of Directors recommends voting for all director nominees, the ratification of Deloitte & Touche LLP, approval of executive compensation, and approval of the Amended and Restated 2023 Equity Incentive Plan.
• The record date for determining stockholders eligible to vote is April 8, 2024.
• The Notice of Internet Availability of Proxy Materials was first mailed to stockholders on or about April 18, 2024.
• In 2023, Inogen had revenue of $315.7 million, a gross margin of 40.1%, and a net loss of $102.4 million.
• Non-GAAP Adjusted EBITDA was negative $37.8 million, and the Non-GAAP Adjusted Operating Loss was $101.9 million.
• Annual bonus plan payouts were made to the senior executive team for 2023 at 25% of target payout levels.
• None of the performance-based equity awards granted to the NEOs in March 2023, 2022, or 2021 vested.
• The Amended and Restated 2023 Equity Incentive Plan includes an increase of 1,200,000 shares for issuance and removes liberal share counting rules for stock options, stock appreciation rights or other awards.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While it outlines positive corporate governance practices and future plans, it also acknowledges financial underperformance in 2023. The overall tone is neutral, aiming to inform stockholders about important decisions and company performance.

Positives

• The Amended and Restated 2023 Equity Incentive Plan includes several features that are consistent with protecting the interests of our stockholders and sound corporate governance practices.
• The Amended and Restated 2023 Equity Incentive Plan prohibits us from re-using shares that are tendered or surrendered to pay the exercise cost or tax obligation for grants of stock options, stock appreciation rights or other awards, shares that have been repurchased by the company on the open market using stock option exercise proceeds, or stock-settled stock appreciation rights where only the actual shares delivered with respect to the award are counted against the plan reserve.

Negatives

• In 2023, Inogen experienced a 16.3% decrease in revenue compared to 2022, with a net loss of $102.4 million.
• Non-GAAP Adjusted EBITDA was negative $37.8 million, reflecting a significant decrease from the previous year.
• Annual bonus plan payouts were made to the senior executive team for 2023 at 25% of target payout levels.
• None of the performance-based equity awards granted to the NEOs in March 2023, 2022, or 2021 vested.

Risks

• The proxy statement highlights the risks associated with the business, including strategic, financial, business and operational, legal and compliance, and reputational risks.
• The company's performance is subject to various market and economic conditions, which could impact its ability to achieve financial targets.
• Failure to attract and retain key personnel could negatively impact the company's operations and growth.

Future Outlook

The company anticipates that the shares available under the Amended and Restated Plan will be sufficient to meet its expected needs through calendar year 2025 and expects to request additional shares under the Amended and Restated Plan at its 2026 annual meeting of stockholders.

Management Comments

• On behalf of the Board of Directors, I would like to express our appreciation for your interest in Inogen, stated Kevin R.M. Smith Chief Executive Officer and President.

Industry Context

Inogen competes with other medical device and diagnostic companies for executive talent. The compensation peer group includes companies with similar financial and growth characteristics in the healthcare equipment, supplies, providers, or services industry.

Comparison to Industry Standards

• The company benchmarks its executive compensation against a peer group of 19 companies, including Alphatec Holdings, Inc, LeMaitre Vascular, Inc, and Merit Medical Systems, Inc.
• The company targets total cash compensation and other executive compensation levels to be within the 50th percentile of its peer group and comparable to similarly situated executives.
• The company's three-year average burn rate and the dilution relating to the initial share reserve is within such guidelines.

Management Changes

Corporate Governance

Stakeholder Impact

• The proposals to be voted on at the Annual Meeting will impact stockholders, employees, and other stakeholders.
• The election of directors will determine the leadership and direction of the company.
• The ratification of the independent auditor will ensure the integrity of the company's financial statements.
• The advisory vote on executive compensation will provide feedback on the company's pay practices.
• The approval of the Amended and Restated 2023 Equity Incentive Plan will impact the company's ability to attract and retain talent.

Next Steps

• Stockholders are urged to submit their vote via the Internet, telephone, or mail.
• The Board and Compensation Committee will consider the outcome of the advisory vote on executive compensation when making future compensation decisions.
• The company will continue to monitor the independence of its compensation consultant on a periodic basis.
• The company expects to request additional shares under the Amended and Restated Plan at its 2026 annual meeting of stockholders.

Key Dates

Keywords

proxy statement, annual meeting, directors, executive compensation, equity incentive plan, Deloitte & Touche LLP, stockholders, corporate governance, financial performance, Inogen